The loss of cholinergic innervation is thought to be responsible for cognitive deficits in AD (31, 33), a hypothesis that underpins the use of cholinesterase inhibitors as the primary clinical strategy to improve memory loss in AD. The gene discussed is BCHE; the disease is Alzheimer disease.